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Abstract
During the last decades, research focused on vaccinia virus (VACV) pathogenesis has been intensified prompted by its
potential beneficial application as a vector for vaccine development and anti-cancer therapies, but also due to the fear of its
potential use as a bio-terrorism threat. Recombinant viruses lacking a type I interferon (IFN) antagonist are attenuated and
hence good vaccine candidates. However, vaccine virus growth requires production in IFN-deficient systems, and thus viral
IFN antagonists that are active in vitro, yet not in vivo, are of great value. The VACV E3 and influenza virus NS1 proteins are
distinct double-stranded RNA-binding proteins that play an important role in pathogenesis by inhibiting the mammalian
IFN-regulated innate antiviral response. Based on the functional similarities between E3 and NS1, we investigated the ability
of NS1 to replace the biological functions of E3 of VACV in both in vitro and in vivo systems. For this, we generated a VACV
recombinant virus lacking the E3L gene, yet expressing NS1 (VVDE3L/NS1). Our study revealed that NS1 can functionally
replace E3 in cultured cells, rescuing the protein synthesis blockade, and preventing apoptosis and RNA breakdown. In
contrast, in vivo the VVDE3L/NS1 virus was highly attenuated after intranasal inoculation, as it was unable to spread to the
lungs and other organs. These results indicate that there are commonalities but also functional differences in the roles of
NS1 and E3 as inhibitors of the innate antiviral response, which could potentially be utilized for vaccine production purposes
in the future.
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Introduction
Vaccinia Virus (VACV) is a member of the Poxviridae family, a
group of large, double-stranded DNA viruses that replicate exclusively
in the cytoplasm of the infected host cell [1,2]. Vaccination with
VACV was directly responsible for the successful eradication of
smallpox, a devastating disease in man caused by variola virus. The
possible re-emergence of variola virus has led to renewed interest in
the study of poxvirus pathogenesis using the in vivo models that are
limited primarily to vaccinia, cowpox, and ectromelia viruses, which
do not cause disease in immunocompetent humans [1,2].
Moreover, the potential use of VACV as a vector for anti-
cancer therapies and vaccine purposes has also renewed interest in
understanding the basis of poxvirus pathogenesis and attenuation.
Recombinant viruses lacking a type I interferon (IFN) antagonist
are attenuated and hence good vaccine candidates [3]. However,
efficient vaccine virus growth requires production in IFN-deficient
systems. Hence, the identification of viral IFN antagonists that are
active in vitro, yet do not contribute to virus virulence in vivo are of
great value.
Poxviruses contain a large array of genes which are used to
evade host immune responses and contribute to pathogenesis
[4,5,6]. VACV encodes multiple proteins that interfere with
complement regulatory proteins, cytokines and chemokines, toll-
like receptors (TLRs), signal transduction pathways, and apoptosis.
[6]. One of the VACV proteins with strong inhibitory activity of
IFN-induced pathways is E3 [7,8,9]. VACV mutants lacking E3
(VVDE3L) only replicate in IFN-incompetent cell systems [9], are
non-pathogenic in mice, yet provide protection against wild-type
virus challenge [10,11]. E3 has two functional domains, one
located at the N-terminus, that is required for its nuclear
localization and Z-DNA binding activity, and which is also
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involved in the direct inhibition of protein kinase R (PKR), and the
dsRNA-binding domain at the C-terminus, required for IFN-
resistance and for the broad host range phenotype of the virus
[10,12,13].
The E3 protein represses the host cell antiviral response by
multiple mechanisms, including inhibition of the two well-
characterized IFN-inducible enzymes PKR and 29-59-oligoadeny-
late synthetase (29-59OAS), both being activated by dsRNA
[8,14,15]. Activation of these two proteins triggers a global
inhibition of protein synthesis, which leads to the induction of
apoptosis and an effective blockade of viral replication [16]. Upon
binding to dsRNA, PKR mediates phosphorylation of the alpha
subunit of the eukaryotic protein synthesis initiation factor (eIF-2a)
leading to a translational block. On the other hand, upon
stimulation, 29-59OAS generated products activate an endogenous
endoribonuclease (RNase L), which cleaves cellular and viral
RNAs [17]. Therefore, the ability of E3 to inhibit activation of
these enzymes is crucial for the maintenance of the cellular
translational function, which is required for active viral replication.
E3 also blocks induction of IFN-a/b through inhibition of
phosphorylation of the IFN regulatory transcription factors 3
(IRF-3) and 7 (IRF-7) [18,19], and prevents nuclear factor kB (NF-
kB) activation [20]. Furthermore, the E3 protein binds to the
protein encoded by IFN-stimulated gene 15 (ISG15), thereby
blocking its antiviral activity [21]. The E3 deleted mutant virus,
VVDE3L, is restricted for replication in many tissue culture
systems, but replicates in double knock-out PKR/RNase L [19] or
ISG15 deficient murine cells [21], and in PKR deficient human
cells [22]. Recently it has been described that the formation of
antiviral granules, due to the phosphorylation of eIF-2a by PKR,
also imposes a restriction on VVDE3L replication in murine cells
[23].
In addition to E3, VACV encodes other proteins that also
inhibit the IFN action. They either prevent IFN binding to its
natural receptor (soluble type I and II IFN-binding proteins) or
block the IFN-signalling cascade or IFN-induced antiviral state
within infected cells [24]. One of these proteins, B19, is a soluble
IFN-a/b receptor that is expressed very early in the infection.
Viruses lacking B19R gene were shown to be attenuated in both
intranasally and intracranially infected mice [25], supporting the
importance of B19 in pathogenesis. Another VACV protein
involved in the ablation of IFN signalling is B8, a soluble IFN-c
receptor, which is also expressed early in infection [26]. However,
the deletion of the B8R gene from the VACV genome did not
attenuate pathogenesis in a mouse model [27].
Influenza virus is a segmented negative-stranded RNA virus
causing significant respiratory infections in humans. This virus
expresses a non-structural protein in infected cells, the NS1
protein, which counteracts the IFN response. Although this
protein does not share significant amino acid identity with the
VACV E3 protein, its functional properties are remarkably similar
to those of the E3 protein.
The N-terminal domain of influenza A virus NS1 protein binds
to dsRNA preventing the dsRNA-mediated activation of 29-
59OAS and RNase L [28]. As E3, NS1 binds directly to PKR and
inhibits its kinase activity [29,30], blocks the induction of IFN-a/b
through inhibition of IRF3 and IRF7 phosphorylation [31] and
prevents NF-kB [32], janus kinase (JNK) and activating transcrip-
tion factor 2 (ATF-2) activation [33]. An influenza virus mutant
lacking NS1 (DNS1) is restricted in replication in IFN-competent
systems, but replicates and induces disease in mice lacking either
PKR or STAT1, a transcription factor required for IFN signalling.
In addition to NS1, the influenza viral polymerase complex has
been also shown to exhibit an inhibitory activity on IFN-b
promoter activation [34]. Moreover, the PB1-F2 90 amino acid
protein expressed from the PB1 gene of some influenza A viruses
has also been shown to suppress IFN-stimulated genes in vitro and
in vivo [35].
Taking the differences and similarities between E3 and NS1 into
account, here, we wanted to investigate the ability of influenza A
NS1 (Puerto Rico/8/34 strain) to replace VACV E3 in both in vitro
and in vivo systems. To this end, we generated a recombinant
VACV lacking E3 but expressing NS1, VVDE3L/NS1. Our study
revealed that NS1 can functionally replace E3 in cultured cells,
inhibiting RNA degradation, protein synthesis blockade and the
apoptotic process, being all of these biochemical effects caused in
cells infected with the E3L deletion mutant, VVDE3L [36].
Although the recombinant VVDE3L/NS1 was able to grow in
VVDE3L non-permissive cultured cells, this virus was unable to
replicate in tissues of infected animals. In fact, our studies revealed
that mice infected with VVDE3L/NS1, like those infected with
VVDE3L, do not show signs of infection, even when high doses of
these viruses were used, while animals infected with wild-type
VACV showed severe weight loss and die a few days after
inoculation. These results indicate that there must be functional
differences between NS1 and E3 as inhibitors of the innate
antiviral response regulated by the IFN system, which are not
apparent in tissue culture, but are highlighted during infection in
an animal model.
Materials and Methods
Cells, viruses, and infections
HeLa (human epithelial cervical cancer cells, ATCC number
CCL-2TM), BSC40 (african green monkey kidney cells, ATCC
number CRL-2761), BHK21 (baby hamster kidney cells, ATCC
number CCL-10) and NIH-3T3 (mouse embryo fibroblast cells,
ATCC number CRL-1658) were grown in Dulbecco’s modified
minimal essential medium (DMEM) containing penicillin (100 U/
ml) and streptomycin (100 mg/ml) and 10% fetal calf serum (FCS)
(Sigma). Wild-type VACV (strain Western Reserve (WR)) and the
recombinant virus expressing the influenza A virus NS1 protein
were grown in monkey BSC-40 cells, purified through two 45%
(w/v) sucrose cushions, and titrated in triplicate by plaque assay on
BSC40 cells [36]. The VACV E3 deletion mutant in which the
E3L gene was fully deleted by being replaced by the E. coli b-
galactosidase coding gene has been previously described [37], and
will be named in this study as VVDE3L for simplicity. VVDE3L
virus was grown in BHK21 cells and titrated by immunostaining
[36]. In brief, BHK21 cells grown in 6 well plates were infected
with serial dilutions of viral extracts and at 18 hours post-infection
(h.p.i.) cells were fixed and permeabilized with Methanol:Acetone
(1:1) for 2 min. Then cells were washed with PBS and incubated
with a polyclonal antibody against VACV proteins [38] diluted
1:1000 in phosphate-buffered saline (PBS) containing 3% FCS
(PBSF). After 90 min incubation at room temperature, cells were
washed twice with PBS and a peroxidase-conjugated goat anti-
rabbit serum diluted 1:1000 in PBSF was added. 90 min later the
wells were washed twice with PBS and 1 ml of a solution
containing 1 mg/ml of diaminobenzydene (DAB), 0.03% hydro-
gen peroxide and 0.03% nickel sulphate diluted in PBS, was added
to each well. The reaction was stopped with PBS when the foci of
infected cells were visible. For tissue culture infections, near-
confluent monolayers of cells were mock-infected or infected with
the different viruses diluted in supplemented DMEM to the
indicated multiplicity of infection (MOI). After 1 h of adsorption at
37uC, virus and medium were removed and replaced with fresh
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DMEM containing 2% FCS. Infected cells were incubated at
37uC until the indicated times p.i.
Engineering of the VACV recombinant viruses
The DNA fragment corresponding to the gene coding for the
NS1 protein from the Puerto Rico/8/34 (H1N1) strain of
influenza A virus (accession number P03496) was cloned into
the Sma I site of the VACV insertion vector pJR101 [39]. The
resulting plasmid, pJRNS1, contains the NS1 gene under the
control of a VACV synthetic early/late promoter, Pse/l, [40], the
E. coli b-glucoronidase marker gene under the control of the VACV
P7.5 early/late promoter, and all these sequences flanked by
regions from VACV hemagglutinin (HA) coding gene (A56R gene).
Insertion of the NS1 gene into VVDE3L genome was achieved by
in vivo recombination between the HA flanking sequences present
in the pJRNS1 vector and the HA locus in the virus genome,
which results in the partial deletion of this viral gene. Specifically,
recombinant viruses VVDE3L/DHA and VVDE3L/NS1 were
obtained by infection of BHK21 cells with the VVDE3L mutant at
0.01 plaque forming units per cell (PFU/cell) and transfection with
the empty pJR101 or pJRNS1 plasmids respectively in presence of
lipofectamine (Invitrogen). Cell cultures were harvested at 48 h.p.i
and the recombinant viruses were selected after plaque assay by
the addition of 5-bromo-4-chloro-3-indolyl-b-D- glucuronic acid
(X-Gluc) substrate to the agar overlay. Similarly, cells infected with
WR virus were transfected with empty pJR101 plasmid to obtain
the VV/DHA control virus.
Quantitative real-time RT-PCR
Total RNA was isolated from purified VACV, VVDE3L or
VVDE3L/NS1-infected (5 PFU/cell) or mock-infected HeLa cells
with Ultraspect-II RNA (Biotecx), following the manufacturer’s
instructions. One mg of RNA was reverse-transcribed using
SuperScript (Invitrogen) with oligo-dT as a primer. A 1:40
dilution of the RT reaction mixture was used for quantitative
PCR. Primers and probe sets used to amplify IFN-b (Hs01077958-
s1), ISG15 (Hs00192713-m1), IL-6 (Hs00174131-m1), IFN-a
(Hs01652729-s1) and ATF-3 (Hs00231069-m1), were purchased
from Applied Biosystems. RT-PCR reactions were performed
according to Assay-on-Demand, optimized for TaqMan Universal
PCR MasterMix, No AmpErase UNG, as described [41]. All
samples were assayed in triplicate. Threshold cycle (Ct) values
were used to plot a standard curve in which Ct decreased in linear
proportion to the log of the template copy number. The
correlation values of standard curves were always .99%.
SDS-PAGE and Western-blot analysis
Following VACV infection, cells were lysed in disruption buffer
(0.5% Triton X-100, 50 mM KCl, 50 mM NaCl, 20 mM Tris-
HCl [pH 7.5], 1 mM EDTA, 10% glycerol, 16Complete protease
inhibitor cocktail (Roche), 25 mM b-glycerophosphate, 1 mM
Na3VO4). Lysates were separated by SDS-PAGE with the same
amount of total protein being loaded into each lane and then
transferred onto nitrocellulose membranes. Immunoblots were
blocked for 1 h in PBS containing 0.05% Tween 20 (PBST) and
5% non-fat dry milk, washed in PBST, and incubated at 4uC
overnight with different primary antibodies in PBST and 1% non-
fat dry milk. The antibodies used in this study were rabbit
polyclonal sera raised against a VACV recombinant virus
expressing b-galactosidase [38], against VACV E3 (a generous
gift of B. Jacobs, Arizona University, Arizona, USA), against
VACV HA (a generous gift from J. Ichihasi, Niigata University,
Niigata, Japan) or against NS1 (a generous gift of J. Ortı´n, Centro
Nacional de Biotecnologı´a, Madrid, Spain). Blocking and primary
antibody incubation for total eIF-2a (Santa Cruz Biotechnology),
pS35 eIF-2a (Invitrogen), and PARP (Cell Signaling) were
performed according to instructions provided by the manufactur-
er. Subsequently, membranes were washed and incubated for 2 h
with horseradish peroxidase-conjugated goat anti-mouse or anti-
rabbit immunoglobulin G (Sigma), and bound antibodies were
detected with the ECL Western-blotting detection reagent (GE
Healthcare).
Viral inoculation of mice and sample collection
C57/BL-6 wild-type, PKR2/2 [42] or ISG152/2 [43] mice (6
to 10 week-old) were inoculated intra-nasally (i.n.) in 25 ml of PBS
with VV/DHA, VVDE3L/DHA or VVDE3L/NS1 at 107, 56106
or 56105 PFU/mouse as indicated. All animals were weighed
immediately before virus inoculation and the following days; mice
were also monitored daily for survival. Animals with .30% loss of
body weight were sacrificed. The results shown represent the mean
values obtained in 3 independent experiments 6 standard
deviation. The overall significance of the curves (P values) was
determined using a two-tailed t test assuming non-equal variance.
In all the cases we obtained P,0.01. Inoculated animals were
sacrificed at various times post-inoculation and organs were
removed aseptically, weighed, homogenized in DMEM (0.1 mg of
tissue/ml), and subsequently assayed in triplicate for viral yield by
standard plaque assay in BSC40 cells for VV/DHA or VVDE3L/
NS1, or by immunostaining assay in BHK21 cells for VVDE3L/
DHA. All animals were handled in strict accordance with good
animal practice as defined by the relevant national, international,
and/or local animal welfare bodies, and with the Spanish Royal
Decree (RD 1201/2005). All animal work was approved by the
Ethical Committee of Animal Experimentation (CEEA-CNB) of
the Centro Nacional de Biotecnologı´a (CNB-CSIC).
Histochemistry
Formalin-fixed lungs from infected mice were resected,
sectioned and stained with hematoxilin and eosin as previously
described [21]. Tissue sections were visualized using a Leica
DMRXA microscope and images captured with the DC100
imaging system (Leica). Three different biological samples were
analyzed.
Results
Generation of the virus VVDE3L/NS1
VVDE3L is unable to replicate in HeLa cells, however, it has
been shown that viral replication can be restored by expressing
other viral dsRNA-binding proteins such as the reovirus s3 [37],
the rotavirus NSP3 [44] and the parapoxvirus Orf virus (OV) E3
homolog [45]. To investigate whether the expression of NS1
protein form influenza A virus (Puerto Rico/8/34 (H1N1) strain)
by VVDE3L could rescue the biological defects of this mutant, we
generated a recombinant virus where the NS1 coding sequence
was inserted into the HA locus (A56R gene) of the VVDE3L
genome. Control viruses based on wild-type VACV or VVDE3L
in which the HA coding gene was also partially deleted (VV/DHA
and VVDE3L/DHA, respectively) were also constructed.
Figure 1A shows a schematic representation of the viruses used
in this study.
The expression of the NS1 protein by VVDE3L/NS1 was
verified by Western-blot analysis of infected BHK21 cells, a cell
line that is permissive to VVDE3L replication most likely due a
deficient IFN-mediated antiviral response [36]. It was also
confirmed that this virus does not express any of the two forms
(25 kDa and 21 kDa) of the E3 protein, as opposed to VACV and
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Figure 1. Generation, characterization, and growth properties of VACV recombinants. A. Schematic representation of the VACV
recombinants used for this study. The mutant virus VVDE3L was generated by replacing the VACV E3L gene by the b-galactosidase (beta-gal)
marker gene [37]. The influenza A (Puerto Rico/8/34) virus NS1 gene was introduced into the HA coding region (A56R gene) of VVDE3L virus together
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VV/DHA (Figure 1B). The reactivity of the same samples with an
antibody against the VACV D13 (65 kDa) protein served as an
infection control and indicated that BHK21 cells were similarly
infected by all viruses used. An anti-tubulin antibody was used for
protein loading control.
The growth kinetics of VVDE3L/NS1 was compared to those
of VVDE3L, VACV and VV/DHA in BHK21 cells. For this,
monolayers of BHK21 cells were infected at low MOI (0.01 PFU/
cell) and at the indicated times p.i. cells and media were collected
together and assayed in triplicate for viral yield quantitation.
VVDE3L/NS1 has recovered the ability to form plaques in
BSC40 cells (not shown), therefore, as for VACV and VV/DHA,
virus yields were determined by plaque assay, whereas VVDE3L
viral titers were determined by immunostaining. Similar yields
were obtained with the four viruses in the permissive BHK21 cells
at the different time points analyzed (Figure 1C).
VVDE3L/NS1 overcomes the characteristic blockade of
VVDE3L to replicate in HeLa cells
Mutant vaccinia viruses lacking E3 display a replication-
defective phenotype in many human cell lines, including HeLa
cells [36]. The main function of E3 in cell culture has been shown
to be the inhibition of dsRNA-dependent PKR activity [7]. Upon
activation through dsRNA binding, PKR phosphorylates the
Ser51 residue of the eIF-2a translation initiation factor [46]. This
leads to the inhibition of both host and viral protein synthesis,
thereby inhibiting viral replication. The replication of VVDE3L
can be partially rescued in HeLa cells in which PKR expression is
suppressed [47]. Since influenza NS1 protein is also known to
prevent PKR activity [48,49] we next wanted to analyze the
phenotype of VVDE3L/NS1 in HeLa cells, non-permissive for
VVDE3L. At high MOI (5 PFU/cell), expression levels of the NS1
protein in VVDE3L/NS1-infected HeLa cells were similar to
those in the infected BHK21 (Figure 1B). Moreover, the
expression of VACV D13 protein in HeLa cells infected with
VVDE3L/NS1 was similar to that observed in cells infected with
wild-type VACV or VV/DHA viruses; however it clearly
diminished to undetectable levels in VVDE3L- and VVDE3L/
DHA- infected cells (Figure 1B).
To study viral growth efficiency, monolayers of HeLa cells were
infected at 0.01 PFU/cell with VACV, VV/DHA, VVDE3L or
VVDE3L/NS1, and cells were harvested at different times p.i. and
viral titers were determined as mentioned above. As expected,
VVDE3L virus did not replicate in HeLa cells (Figure 1D).
However, introduction of the NS1 gene into the virus genome
rescued its ability to replicate in these cells. Similar viral
replication curves were observed after VACV, VV/DHA or
VVDE3L/NS1 infection. As detected by Western-blot with an
anti-VACV polyclonal antibody, viral protein accumulation at 8
and 24 h.p.i. was also increased in VVDE3L/NS1-infected cells as
compared to cells infected with VVDE3L (Figure 2A). Differential
bands between wild-type VACV- and VVDE3L/NS1-infected
cells observed in the Western-blot correspond to the HA protein
(denoted with an asterisk), as confirmed by the reactivity with an
anti-HA specific antibody, and the b-galactosidase protein
(denoted with two asterisks), expressed by wild-type VACV- and
VVDE3L/NS1, respectively. These results indicate that viral
protein synthesis and viral growth are rescued in the presence of
NS1. As it has been previously described [50], the translational
blockade observed in VVDE3L-infected HeLa cells coincided with
the phosphorylation of eIF-2a (Figure 2B). No eIF-2a phosphor-
ylation was observed in VACV- or VVDE3L/NS1-infected HeLa
cells. Therefore these findings show that in the context of VACV
infection NS1 is able to block the eIF-2a phosphorylation
mediated by PKR, restoring viral protein synthesis. Next, we
investigated whether VVDE3L/NS1 is resistant to IFN treatment.
Infection with VV/DHA and VVDE3L/NS1 viruses in BHK21
cells pretreated with different doses of IFN-b (from 0 to 1000 U/
ml) indicated that both viruses exhibit similar resistance to IFN
inhibition, whereas VVDE3L is highly sensitive (data not shown).
Overall, the results obtained above indicate that NS1 is able to
restore to VVDE3L the capacity to replicate in HeLa cells and the
IFN resistance phenotype.
NS1 blocks the induction of immunomodulatory
molecules and activation of IFN pathways in cultured
cells infected with VVDE3L/NS1
VVDE3L virus was previously shown to elicit high expression of
specific immunomodulatory molecules such as TNF-a, IFN-b,
IFN-a, IL-6 and ISG15 in HeLa cells [51]. We investigated if the
presence of NS1 was sufficient to inhibit the upregulation of these
molecules. To that end, we evaluated the mRNA levels of TNF-a,
IFN-b, IFN-a, IL-6 and ISG15 in VACV-, VVDE3L- or
VVDE3L/NS1-infected HeLa cells by real-time RT-PCR and
compared them to those in mock-infected cells. During VVDE3L
infection high levels of TNF-a, IFN-b, IFN-a, IL-6 and ISG15
mRNA were detected, which is in accordance with previous
publications [51]. However, infection with VACV or VVDE3L/
NS1 prevented induction of those mRNAs (Figure 2C). It has been
described that E3 protein can suppress a diverse array of cytokines,
produced through both PKR-dependent and PKR-independent
pathways [52]. IL-6 and IFN-b expressions are completely PKR-
independent, however induction of TNF-a requires only PKR-
dependent NF-kB activation [52]. Our results revealed that
expression of NS1 in the context of VACV infection suppresses the
pro-inflammatory signal transduction pathways in a similar way as
the E3 protein.
NS1 inhibits apoptosis and prevents RNA degradation
that characterizes VVDE3L infections
Because it has been demonstrated that VVDE3L infection
triggers programmed cell death and RNase L-mediated RNA
degradation in HeLa cells [7], we wanted to know if NS1
expression could replace E3 in these inhibitory functions.
Apoptosis is mediated by activation of caspase-8 or -9, leading
with the E. coli b-glucuronidase (beta-gus) marker gene to allow the selection of the VVDE3L/NS1 recombinant virus. Control viruses VV/DHA and
VVDE3L/DHA were generated by introducing the b-glucuronidase gene into the HA locus of VACV and VVDE3L genomes, respectively. The VACV P7.5
and Pse/l promoters are indicated. B. Analysis of E3 and NS1 protein expression by recombinant viruses. Extracts from BHK21 (left panels)
or HeLa (right panels) cells mock-infected (MOCK) or infected (MOI 5) for 24 h with VACV, VV/DHA, VVDE3L, VVDE3L/DHA or VVDE3L/NS1 were
separated by SDS-PAGE. Proteins transferred to nitrocellulose membranes were detected with antibodies against VACV E3 and influenza A virus NS1
proteins. E3L gene directs the synthesis of two proteins of 25 kDa and 20 kDa, of which the latter was previously suggested to be a product of
internal initiation. As a control for viral infection an antibody against the VACV D13 protein was also used. Tubulin was detected as a protein loading
control. C and D. Growth curves of mutant viruses in permissive BHK21 (C) or non-permissive HeLa cells (D). Infected cells (0.01 PFU/
cell) were harvested at different times p.i. and virus yields were determined by plaque assay (VACV, VV/DHA, VVDE3L/NS1) or by immunostaining
(VVDE3L). Results represent the mean 6 the standard deviation of three independent experiments.
doi:10.1371/journal.pone.0028677.g001
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to induction of effector caspases-3 and -7, which cleave specific
substrates, including poly (ADP-ribose) polymerase-1 (PARP-1).
This enzyme catalyzes the formation of poly (ADP-ribose)
polymers on acceptor proteins involved in the maintenance of
chromatin structure. The presence of an 89 kDa PARP-1 cleavage
product indicates the activation of the apoptotic cascade [53]. We
monitored apoptosis by comparing cellular morphological changes
in HeLa cells infected with wild-type VACV, VVDE3L and
VVDE3L/NS1 and assessing cleavage of PARP-1 at different
times p.i. We also examined ribosomal rRNA degradation as an
indication of RNase L activation. The morphological signs of
apoptosis observed in VVDE3L-infected HeLa cells at 24 h.p.i.
were not evident after infection with VVDE3L/NS1 (Figure 3A).
In addition, as VACV, VVDE3L/NS1 was able to prevent the
characteristic cleavage of PARP-1 observed in VVDE3L-infected
cells at 24h.p.i. (Figure 3B). Similarly, rRNA degradation was only
observed in VVDE3L-infected cells (Figure 3C). These findings
suggest that NS1 is able to prevent apoptosis and RNase L activity,
thereby preventing host rRNA degradation.
NS1 cannot substitute E3 in vivo
To determine if the introduction of the NS1 gene into VVDE3L
genome alters the attenuated phenotype of the virus in vivo, we set
out to infect mice with the different mutant viruses. To ensure that
all mutant viruses behaved phenotypically similar in human and
mouse cells, we infected monolayers of mouse NIH-3T3 cells at
0.01 PFU/cell with VACV, VV/DHA, VVDE3L or VVDE3L/
NS1, harvested at different times p.i. and measured viral titers. As
expected, similar to what occurs in human cells, VVDE3L virus
did not replicate in NIH-3T3 cells (Figure S1). In contrast,
VVDE3L/NS1 was able to replicate to the same level that VACV
and VV/DHA (Figure S1). This indicates that the mutant viruses
exhibit the same phenotype in human and mouse cells.
Next, C57/BL-6 mice were infected i.n. with three challenge
doses of VVDE3L/DHA or VVDE3L/NS1 (107, 56106 or
56105 PFU/mouse) or the two lower doses (56106 or
56105 PFU/mouse) of VV/DHA. Infected mice were scored for
weight loss and mortality over a period of one week as prominent
indicators of viral pathogenesis. In contrast to VV/DHA infection,
which caused drastic body weight loss and severe signs of illness,
infection of mice with VVDE3L/DHA or with the recombinant
VVDE3L/NS1 did not cause any obvious disease, even at the
highest dose used (Figure 4A). Mice infected with 56106 PFU/
mouse of VV/DHA started dying at 5 days p.i., and by day 7th all
mice had died. In contrast, all mice infected with VVDE3L/NS1
virus survived. This result revealed that introduction of the NS1
gene into the backbone of VVDE3L does not modify the
attenuated phenotype of the E3L-deleted virus in mice.
In the mouse model, i.n. inoculation of wild-type VACV results
in an acute infection of the lung followed by subsequent spread of
the virus to visceral organs. To determine viral dissemination in
the animal we analyzed viral titers in homogenates of trachea,
lung, liver and spleen obtained at day 3 after infection with the
different viruses. We found VV/DHA virus in the trachea, from
where the virus had progressed to the lungs, liver and spleen of
infected animals. Viral titers were .1000-fold higher in all tissues
from VV/DHA infected animals than in those from animals
infected with the VVDE3L/DHA control virus (Figure 4B).
Consistent with the survival data, NS1 expression did not rescue
viral replication (Figure 4B). Hematoxylin and eosin stained
histological sections of lung tissue from animals infected with the
different viruses (56106 PFU/mouse) were examined at 3 days p.i.
Lung sections obtained from VVDE3L/DHA- or VVDE3L/NS1-
infected mice showed no inflammatory cells infiltrating the lung
parenchyma. In contrast, VV/DHA-infected mice presented
severe inflammation with alveolar wall thickening and infiltration
of inflammatory cells (Figure 4C; insets).
Since the VVDE3L/NS1 was not pathogenic in wild-type mice,
we reasoned that the virus cannot counteract effectively some of
the IFN-induced pathways responsible for mounting the antiviral
response. To test if either PKR and/or ISG15 proteins were
responsible for the in vivo restriction of this virus, we infected
PKR2/2 [42] and ISG152/2 [43] mice with the mutant viruses.
VVDE3L/NS1 was neither lethal in mice lacking PKR (Figure
S2), nor in ISG152/2 mice (Figure S3). In both knock-out mouse
strains no signs of pathogenesis were detected after the infection
with VVDE3L/NS1, whereas loss of weight and animal death
were observed among VACV infected mice (Figures S2 and S3).
Since the VVDE3L/NS1 virus grows to high titers in tissue
culture, yet is attenuated in vivo, it could be of interest for future
vaccine development. To investigate if the VVDE3L/NS1 virus
still elicits immune responses that protect from wild-type VACV
challenge, we pre-immunized wild-type mice with VVDE3L/DHA
or VVDE3L/NS1 by i.n. route and subsequently challenged them
with 26107 PFU/mouse of wild-type VACV. VVDE3L/DHA- or
VVDE3L/NS1-immunized mice did neither lose weight nor
developed other signs of illness (Figure S4), indicating that both
groups of animals were protected similarly against a lethal VACV
challenge. These findings demonstrate that although VVDE3L/
NS1 replicates poorly in vivo, it is able to confer protection to
challenge with VACV, similar to what occurs with VVDE3L [54].
However, since VVDE3L/NS1, in contrast to VVDE3L, grows to
high titers in vitro, it may hold a promising strategy for vaccine
development.
Discussion
Since the IFN-induced cellular antiviral response is the primary
defense mechanism against virus infections, many viruses have
developed a number of strategies to counteract IFN-dependent
Figure 2. VVDE3L/NS1 blocks eIF-2a phosphorylation and proinflammatory cytokine production in infected HeLa cells. A. Viral
protein expression. HeLa cells were mock-infected (MOCK) or infected with VACV, VVDE3L or VVDE3L/NS1 (5 PFU/cell). Cells were collected at the
indicated times p.i., and equal amounts of total protein from cell extracts were separated by SDS-PAGE, transferred to nitrocellulose, and treated with
a polyclonal antibody against a VACV recombinant virus that expresses the b-galactosidase gene. An anti-VACV HA antibody was used to confirm the
lack of expression of this protein by the recombinant viruses. Actin was used as a protein loading control. The position of HA in VACV infected cells is
indicated by an asterisk. The position of b-galactosidase protein observed in VVDE3L/NS1 is denoted by two asterisks. B. eIF-2a phosphorylation
levels during VACV, VVDE3L or VVDE3L/NS1 infection. HeLa cells were mock-infected (MOCK) or infected with VACV, VVDE3L or VVDE3L/NS1
(5 PFU/cell). Cells were collected at the indicated times p.i., and equal amounts of total protein from cell extracts were fractionated by SDS-PAGE,
transferred to nitrocellulose and incubated with antibodies to total eIF-2a or eIF-2a phosphorylated at Ser51. C. Relative expression levels of
genes involved in the immune response determined by real time RT-PCR. HeLa cells were mock-infected (MOCK) or infected with VACV,
VVDE3L or VVDE3L/NS1 (5 PFU/cell) and processed for real time RT-PCR at 6 h.p.i. The name of each gene product and the data values obtained in RT-
PCR are indicated. X-Fold gene induction (x-axis) was quantified by real time RT-PCR in three independent experiments. Standard deviation is
indicated.
doi:10.1371/journal.pone.0028677.g002
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Figure 3. NS1 expression by VACV mutants prevents apoptosis and rRNA degradation. A. Morphological changes in HeLa cells
mock-infected or infected with VACV, VVDE3L and VVDE3L/NS1 (5 PFU/cell). Cell morphology was examined at 16 h.p.i by phase-contrast
microscopy. B. Time course of PARP-1 cleavage during VACV, VVDE3L or VVDE3L/NS1 infection. HeLa cells were mock-infected (MOCK) or
infected with VACV, VVDE3L or VVDE3L/NS1 (5 PFU/cell). At the indicated times p.i. cells were harvested and total proteins were separated by SDS-
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pathways, and specifically to avoid the deleterious effects of the
PKR and 29-59 oligoadenylate synthetase/RNase L system. E3
and NS1, from poxvirus and orthomyxovirus, respectively, are
both dsRNA-binding proteins highly specialized in blocking
cellular defense mechanisms, interfering with these pathways at
different levels. These viral inhibitors are normally expressed from
the onset of infection to maintain the IFN system inactive until the
virus cycle is completed. Elimination of these IFN inhibitors from
these viruses generally has a severe impact on virus replication and
pathogenesis. VVDE3L is a virus that only replicates in IFN-
incompetent systems [19], is nonpathogenic in the mouse model,
and provides protection against a wild-type VACV virus challenge
[54].
Here, we describe that the replacement of E3L gene with NS1
resulted in a recombinant virus, VVDE3L/NS1, that replicated as
efficiently as wild-type VACV in cells in culture but was debilitated
in pathogenesis in the animal model. These results suggest that in
the context of VACV, NS1 is able to block, with the same efficacy as
E3, the IFN-based antiviral defense that operates in the VACV in
vitro infection. One of the main functions of E3 in cell culture has
been shown to be the inhibition of dsRNA-dependent PKR activity
[7], and the consequent phosphorylation of the eIF-2a translation
initiation factor [46]. In the absence of E3, eIF-2a phosphorylation
leads to the inhibition of host and viral protein synthesis, thereby
inhibiting VVDE3L replication, and inducing apoptosis. The
replication of VVDE3L and induction of apoptosis can be both
partially rescued in HeLa cells in which PKR expression is
suppressed [47]. The absence of eIF-2a phosphorylation in
VVDE3L/NS1-infected HeLa cells correlates with the rescue of
viral protein synthesis and prevention of apoptosis, indicating a
possible inhibition of PKR after NS1 expression. This observation is
in concordance with previous results using other systems that show
that NS1 prevents the activation of PKR [48,49]. In addition,
VVDE3L/NS1 is not only able to grow in HeLa cells, but it is also
resistant to IFN treatment to the same levels as VACV. Elegant
studies have been performed to identify those E3 regions involved in
dsRNA binding necessary to mediate the VACV IFN resistance
phenotype and the ability to replicate in HeLa cells [55]. In these
experiments Shors et al. demonstrated that recombinants contain-
ing an E3L gene with deletions of 37 (VVE3LD37N) or 83
(VVE3LD83N) amino acids from its N-terminus were IFN resistant
and able to replicate in HeLa cells, indicating that those regions
have no effect on dsRNA binding activity or PKR inhibition [55].
However, recombinant VACV containing an E3L gene deletion of
26 amino acids from its C-terminus (VVE3LD26C) or a point
mutation at glycine 164 that completely abrogates dsRNA binding
activity [13], were both sensitive to the effects of IFN and unable to
replicate in HeLa cells. The result obtained here suggest that in
infected cultured cells NS1 complements the functions conferred by
the E3 C-terminus, hence allowing VVDE3L/NS1 replication in
HeLa cells and conferring IFN resistance.
Despite the complementation observed in vitro, expression of
NS1 by VVDE3L/NS1 does not contribute to increase the
pathogenicity of the E3L deletion mutant. Although it has been
shown that the presence of the entire E3 is required for
pathogenesis [10] [12], Langland et al. showed that there are
different behaviors between several E3L deletion mutants viruses
(VVDE3L, VVE3LD26C, VVE3LD83N) regarding the induction
of proinflammatory cytokines [51]. They speculate that the rate of
expression of host inflammatory genes induced during infection
with these mutants and VACV (VVDE3L.VVE3LD26C.V-
VE3LD83N.VACV) is inversely proportional to the virulence
associated with these viruses, indicating that these pathways and
inflammatory genes could be responsible for limiting the
replication of some of these mutant viruses [51]. However,
VVDE3L/NS1 is able to block proinflammatory gene expression
and, nonetheless, is highly attenuated in vivo. Although we cannot
discard the contribution of proinflammatory cytokines in dimin-
ishing VACV pathogenesis in the absence of E3, our results
suggest that they do not play a crucial role.
The E3 molecule is a conserved feature amongst orthopox-
viruses. Vijaysri et al. [56] showed that the expression of the OV
E3 homologue was able to complement the deletion of VACV E3L
gene in vitro but not in vivo [56]. These authors generated chimeric
viruses and demonstrated that the N-terminal domain of OV E3
could substitute the function of the N-terminal domain of VACV
E3 in vivo. The N-terminal domains from vaccinia, Orf, lumpyskin,
swinepox, and yaba-like disease viruses have sequence similarity to
a family of Z-DNA binding proteins of defined three-dimensional
structure and the results obtained by these authors suggest that
there is also functional conservation between VACV and OV E3
N-terminal domains. In contrast, the C-terminal domain of OV
E3 could not substitute the VACV counterpart. Since the C-
terminal domain of E3 is involved in dsRNA binding, these results
suggest that OV E3 may bind dsRNA differently in comparison to
VACV E3. The in vivo phenotype of VVDE3L/NS1 suggests that
the absence of the unique N-terminal Z-DNA binding domain of
E3 and/or the presence of a different dsRNA domain could be
responsible for the lack of virulence.
On the other hand the in vivo replication blockade of VVDE3L/
NS1 appears to be PKR and ISG15 independent since the virus
was neither pathogenic in PKR and ISG15 knockout mice. Hence,
we reasoned that additional IFN-induced pathways are effectively
mounting an antiviral response against this virus in vivo.
Overall, these results would suggest that since NS1 fully restores
the functionality of E3 in cultured cells, but E3 is still required for
VACV virulence, probably E3 exerts additional function(s)
essential for its virulence in vivo that could not be covered by NS1.
One of the additional functions encoded by E3 that NS1
probably lacks, would be the ability to inhibit cytosolic dsDNA
sensing pathways, which are activated after VACV infection due to
its cytoplasmic replication. One of the molecules involved in these
pathways is the DNA-dependent activator of IFN regulatory factors
(DAI). As mentioned before, the E3 N-terminus contains a Z-DNA-
binding domain, which shows high amino acid homology to the
corresponding domain of DAI [57]. The finding that the
substitution of the E3 N-terminus by the dsDNA binding domain
from DAI or adenosine deaminase 1 (ADAR1), another Z-DNA-
binding protein, does not affect VACV virulence, suggests that
dsDNA binding functions in the E3 N-terminus regulate VACV
pathogenesis [58]. However, recently it has been demonstrated that
the ability of E3 to block signaling in response to dsDNA maps
entirely to the C-terminal dsRNA-binding domain, indicating that
the binding of the E3 N-terminus to cytoplasmic dsDNA is not
responsible of the virulence regulating function [59]. Therefore, the
function of the N terminus in virulence still remains unclear [9] [45].
PAGE, transferred to nitrocellulose and immunoblotted with anti-PARP-1 antibody. An 89 kDa PARP-1 cleavage product is observed at 24 h.p.i in
VVDE3L infected cells. The expression of VACV D13L and E3 and recombinant NS1 proteins was examined as control of viral infection. C. rRNA
degradation. Total rRNA was isolated from HeLa cells mock-infected (MOCK) or infected with VACV, VVDE3L or VVDE3L/NS1 (5 PFU/cell) at
indicated times p.i. Each sample was analyzed by electrophoresis and subsequent staining with ethidium bromide.
doi:10.1371/journal.pone.0028677.g003
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Figure 4. The expression of influenza virus NS1 protein does not modify the attenuated phenotype of VVDE3L in vivo. A. C57/BL6
mice were infected i.n. with three doses of VVDE3L/DHA or VVDE3L/NS1, (107, 56106 or 56105 PFU/mouse) and two doses of VV/DHA (56106 or
56105 PFU/mouse). Weight and survival rates were monitored. Survival curves are shown in the upper panels. The percentage of weight loss of each
animal with respect to the initial weight at the starting of the experiment was calculated, and the mean values of four animals per group are
represented (lower panels). The error bars represent standard deviation. B. Quantitative analysis of viral replication in the lung, trachea, liver, and
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The proposed ability of E3 N-terminus and other Z-DNA-binding
proteins to regulate additional pathways involved in the host
response, [60], as is the cellular transcription [51], could be a
particular characteristic of E3, and probably an essential require-
ment to allow a virulent phenotype in the in vivo infection.
In the context of influenza infection NS1 is an essential
requirement to abolish the IFN activity and to achieve virulence.
However, in addition to NS1, the influenza viral polymerase
complex has been also shown to exhibit an inhibitory activity on
IFN-b promoter activation [34]. More recently, the PB1-F2 90
amino acid protein expressed from the PB1 gene of some influenza
A viruses has also been shown to suppress IFN-stimulated genes in
vitro and in mice [35]. We can speculate the possibility of a
synergistic function of the PB1 gene product together with NS1. In
this regard, to further investigate the specific contribution of these
factors in the blockade of the IFN system in vivo it could be
interesting to study the effect of the co-expression of NS1 and PB1
genes in the VACV context regarding the restoration of the
virulent phenotype. Also, studying the in vivo phenotypic effect of
the substitution of NS1 by E3 could help to define more
specifically the functional similarities and differences between
these two important immunomodulator proteins.
On the other hand, despite the highly attenuated phenotype of
the VVDE3L/NS1 virus, preimmunization of mice with this virus
confers protection against a lethal challenge with wild-type VACV,
indicating that this virus is able to elicit a strong immune response.
In conclusion, even though NS1 can functionally substitute E3 in
cultured cells, in mice E3 is required for VACV virulence. This
result suggests that E3 exerts additional roles required for VACV
pathogenesis that are absent in NS1 protein. Apart from being a
valuable tool to study the role of E3L gene in the virulence of
poxviruses, this recombinant construct may prove to be a promising
vector for use in recombinant vaccines and anticancer therapy.
Supporting Information
Figure S1 VVDE3L/NS1 is able to grow in murine cells.
Growth curves of VACV, VV/DHA, VVDE3L, and VVDE3L/NS1
in NIH/3T3 cells. Infected cells (0.01 PFU/cell) were harvested at
different times p.i. and virus yields were determined by plaque assay
for VACV, VV/DHA or VVDE3L/NS1 or by immunostaining for
VVDE3L or VVDE3L/DHA. Results represent the mean 6 the
standard deviation of three independent experiments.
(TIF)
Figure S2 PKR deficiency does not contribute to
VVDE3L/NS1 pathogenesis. Weight and survival rates of
PKR2/2 and their wild-type counterparts C57/BL6 mice infected
i.n. with VACV, VVDE3L or VVDE3L/NS1 at 56106 or
56105 PFU/mouse. The percentage of weight loss of each animal
was established by comparing with its starting weight before
infection, and error bars indicate the standard deviation for each
group of 5 mice. P values from a two-tailed t test assuming non-
equal variance were calculated. In all the cases we obtained
P,0.01.
(TIF)
Figure S3 ISG15 deficiency does not contribute to
VVDE3L/NS1 pathogenesis. Weight and survival rates of
ISG152/2 and their wild type counterparts C57/BL6 mice infected
i.n. with VACV or VVDE3L/NS1 at 56106 or 56105 PFU/mouse.
The percentage of weight loss of each animal was established by
comparing with its starting weight before infection, and error bars
indicate the standard deviation for each group of 5 mice. P values
from a two-tailed t test assuming non-equal variance were
determined. In all the cases we obtained P,0.01.
(TIF)
Figure S4 Infection with VVDE3L/NS1 protects mice
from lethal WR challenge. A. Quantitative analysis of the
survival and loss of weight C57/BL6 mice primed i.n. with
56105 PFU/mouse of VVDE3L/DHA or VVDE3L/NS1 and
challenged by i.n. route with VACV at 26107 PFU/mouse. The
percentage of weight loss of each animal was established by comparing
with its starting weight before infection and error bars indicate the
standard deviation for each group of 5 mice. P values from a two-tailed
t test assuming non-equal variance are indicated, P,0.01.
(TIF)
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